No Data
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
BTIG analyst Julian Harrison maintains $Aclaris Therapeutics(ACRS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 52.7% and a total average return of 15.8% over
Aclaris Therapeutics' ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
Express News | Aclaris Therapeutics Inc - Topline Data Expected in First Half of 2025
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Express News | Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent Itk/Jak3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis